Scientific article
OA Policy
English

New treatment for non-Hodgkin B-cell lymphomas with a special focus on the impact of junctional adhesion molecules

Published in

Swiss Medical Weekly, vol. 147, w14487

Publication date

2017

Abstract

Current therapeutic modalities used for B-cell lymphoma include chemotherapy, immunotherapy, and radiation therapy. Chemotherapy together with anti-CD20 monoclonal antibodies forms the cornerstone of therapy and has a curative, as well as a palliative, role in this disease. New treatment modalities targeting specific molecules on the surface of lymphoma cells or intracellular pathways regulating apoptosis, proliferation and cell division are intensively investigated. One such target is JAM-C, a molecule implicated in cell adhesion and in B cell migration and whose inhibition blocks B cells from reaching their supportive microenvironments in lymphoid organs. Hopefully this and other strategies will help to improve survival of B cell lymphoma patients in the future.

Citation (ISO format)

IMHOF, Beat Albert, MATTHES, Thomas. New treatment for non-Hodgkin B-cell lymphomas with a special focus on the impact of junctional adhesion molecules. In: Swiss Medical Weekly, 2017, vol. 147, p. w14487. doi: 10.4414/smw.2017.14487

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

1424-7860
539views
587downloads

Technical informations

Creation

16/11/2017 08:29:00

First validation

16/11/2017 08:29:00

Update

15/03/2023 02:21:48

Status update

15/03/2023 02:21:48

Last indexation

31/10/2024 08:36:00
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated